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Staphylococcus aureus is one of the most common causative pathogens of bloodstream infections (BSIs). In
approximately one-half of patients with S. aureus BSI, no portal of entry can be documented. This group of
patients has a high risk of developing septic metastases. Similarly, patient populations at high risk of S. aureus
BSI and BSI-associated complications include patients receiving hemodialysis, injection drug users, patients
with diabetes, and patients with preexisting cardiac conditions or other comorbidities. One of the most severe
complications of S. aureus BSI is infective endocarditis, and S. aureus is now the most common cause of
infective endocarditis in the developed world. Patients with methicillin-resistant S. aureus BSI or infective
endocarditis have higher rates of mortality, compared with patients with methicillin-susceptible S. aureus
infection. Nasal carriage is the most important source of S. aureus BSI. Better eradication and control strategies,
including nasal decolonization and more-active antibiotics, are needed to combat S. aureus BSIs.
Bacteremia is defined as the presence of viable bacteria
in the blood and is not necessarily associated with clin-
ical manifestations of disease [1]. The term bloodstream
infection (BSI) has been imposed progressively, and a
diagnosis of BSI requires the presence of clinical symp-
toms of systemic infection in addition to positive blood
culture results [2]. BSIs are associated with significant
morbidity and mortality, particularly in populations at
high risk of infection.
Staphylococcus aureus is the second-most common
pathogen causing BSIs worldwide [3, 4], and S. aureus
is the leading cause of nosocomial BSIs in Europe [4].
In the United States, S. aureus is the pathogen that is
most frequently isolated from all types of BSI [5]. S.
aureus BSIs are associated with a high frequency of life-
threatening complications, such as metastatic infec-
tions, and S. aureus is the principal pathogen respon-
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sible for infective endocarditis (IE) in industrialized
countries [6–16]. Patients with S. aureus IE are more
clinically debilitated and have a higher prevalence of
severe sepsis, major neurological events, and multiple
organ failure, compared with patients with IE caused
by other pathogens [16, 17]. As a result, S. aureus BSIs
have a significant impact on mortality, with docu-
mented associated mortality rates of 20%–40% [18].
This relatively wide range of reported mortality rates
may be reflective of the different characteristics of spe-
cific study populations, and patients with prosthetic
devices or long-term intravascular catheters may be
particularly vulnerable. A study that involved 298 pa-
tients with prosthetic devices (long-term catheters and
cardiovascular, orthopedic, and other devices) reported
an in-hospital S. aureus–associated mortality rate of
12%, with a 12-week mortality rate of 17%. Mortality
rates among patients with cardiovascular prostheses
were considerably higher; the in-hospital S. aureus–
associated mortality rate was 18%, and this mortality
increased to 26% at 12 weeks of follow-up [10]. An
overall mortality rate of 19% was observed among pa-
tients who received long-term hemodialysis [19]. Nos-
ocomial S. aureus BSI dramatically increases the cost
of hospitalization, and these costs are further increased
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by methicillin resistance in pathogens causing complicated BSIs,
including those associated with endocarditis, osteomyelitis, and
deep-seated abscesses [10, 19, 20]. Because of the high mor-
bidity and mortality associated with BSIs, efforts to identify
patients at high risk of developing BSI and associated compli-
cations have intensified.
EPIDEMIOLOGY OF BSIS
Classically, BSIs are stratified according to the environment of
acquisition (nosocomial or community-acquired BSIs [CA-
BSIs]) and by the presence or absence of identified associated
sites of infection. The recent delineation of health care–asso-
ciated BSIs (HCA-BSIs), which are more closely related to nos-
ocomial BSIs than to CA-BSIs, allows us to define more pre-
cisely the population at risk of S. aureus BSI (table 1). The
features of HCA-BSIs are not consistently defined among stud-
ies; however, most authors identify previous hospitalization,
receipt of long-term hemodialysis, and residence in a nursing
home or long-term care facility as the most important char-
acteristics [5, 21, 22]. Nosocomial BSIs and HCA-BSIs are most
frequently associated with intravascular devices [21]. Rates of
methicillin resistance among strains causing nosocomial BSIs
and HCA-BSIs are generally similar [5, 21] and are higher than
those among strains causing CA-BSIs [5]. In a large US study,
the frequency of S. aureus causing HCA-BSIs, nosocomial BSIs,
and CA-BSIs was 25.7%, 29.7%, and 17.8%, respectively, and
the frequency of methicillin-resistant strains causing these in-
fections was 41%, 52%, and 26%, respectively [5].
Although S. aureus is less frequently isolated from CA-BSIs
than from nosocomial BSIs or HCA-BSIs, S. aureus CA-BSI
remains a serious condition and is associated with high rates
of complications and mortality [23]. Analysis of patients with
S. aureus BSI at a tertiary care center in Switzerland revealed
that mortality among patients with CA-BSI was twice as high
as mortality among patients with nosocomial infection [24],
probably because primary BSIs, which are a potential severity
factor (see below), occurred more frequently in the patients
with CA-BSI. In addition, patients with CA-BSI may have pro-
longed undiagnosed S. aureus bacteremia, and patients with
nosocomial BSI usually receive a diagnosis relatively early. His-
torically, methicillin-resistant S. aureus (MRSA) has been as-
sociated primarily with nosocomial BSIs; however, community-
acquired MRSA (CA-MRSA) strains with the Panton-Valentine
leukocidin locus are causing an epidemic in the United States
and are now emerging throughout the world and becoming a
cause of a significant proportion of S. aureus infections in sur-
veillance studies [25–29]. Of particular concern is CA-MRSA
infection in patients with no known risk factors for BSI [27,
30]. CA-MRSA strains are generally susceptible to non–b-lac-
tam antibiotics; however, the increasing proportion of CA-
MRSA infections that are caused by highly virulent strains,
together with the emergence of multidrug-resistant strains, em-
phasizes the importance of rapid initiation of appropriate treat-
ment [31–33].
PRIMARY VERSUS SECONDARY BSIS
A primary BSI is traditionally defined as a BSI associated with
bacteremia for which there is no identified portal of entry or
associated infected site [1]. Primary BSI accounts for 40%–50%
of cases of S. aureus bacteremia and occurs much less frequently
in patients with nosocomial bacteremia (3%–5%) than it does
in patients with community-acquired bacteremia [24, 34]. A
secondary BSI is defined as a BSI in which there is a docu-
mented portal of bacterial entry (e.g., a skin infection, a cath-
eter, pneumonia, or a urinary tract infection) and/or a known
associated site of infection. Infections frequently associated with
secondary BSIs include endocarditis, deep-seated abscesses, and
osteomyelitis [35]. It is useful to consider primary BSI as part
of a continuum of pathology from the initial undetected bac-
teremia to the secondary seeding of sites (figure 1). These sites
may have been seeded either from a primary BSI, if there is
bacteremia without a documented portal of entry, or from a
secondary BSI, if a portal of entry or primary infection has
been established. Therefore, it is clearer to distinguish primary
and secondary BSIs on the criterion of an identified portal of
entry.
S. AUREUS BSI: THE RISK OF COMPLICATIONS
Approximately one-third of patients with S. aureus BSI develop
local complications or distant septic metastases [11, 35]. Frequent
sites of distant metastases include the bones and joints (especially
when prosthetic materials are present), the epidural space and
intervertebral discs, and both native and prosthetic cardiac valves.
In addition, patients can develop visceral abscesses in the spleen
and kidneys. Fowler et al. [35] investigated clinical characteristics
that might predict the likelihood of complications developing.
The authors identified 4 risk factors associated with complicated
S. aureus BSIs: namely, the presence of persistent bacteremia
(positive blood culture results after 72–96 h of appropriate treat-
ment), community acquisition, the presence of skin lesions sug-
gestive of distant metastases, and persistent fever. In the absence
of any of these risk factors, the probability of developing com-
plications was 16%; this risk increased dramatically when1 of
these risk factors were present [35]. A delay in the administration
of appropriate treatment has also been associated with an increase
in the risks of complications [3] and higher mortality [36]. These
data suggest that persistent bacteremia should alert the clinician
to the potential for complications and should prompt further
investigation.
Endocarditis is one of the most severe complications of S.
aureus BSI, and native-valve S. aureus IE has a poorer prognosis
than does IE caused by other pathogens [37]. Several studies
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Table 1. Definitions of bloodstream infections (BSIs) according to means of
acquisition.
Category Definition
HA-BSI Patients with a first positive blood culture result 12 days after hospital
admission and 1 day after hospital discharge
HCA-BSI Patients with a first positive blood culture result 12 days after hospital
admission and any of the following:
●hospitalization in an acute care hospital for 2 days in the past 90
days,
●residence in a nursing home or long-term care facility,
●receiving long-term hemodialysis,
●receiving IV therapy at home,
●previous hospitalization within 2–30 days before hospital admission, or
●currently receiving immunosuppression medication or presence of met-
astatic cancer
Patients with long-term intravascular devices to receive either chemo-
therapy or parenteral nutrition
Patients who underwent an invasive procedure that required hospital ad-
mission or with BSI occurring within the first 48 h after hospital
admission
CA-BSI Patients who do not meet HA-BSI or HCA-BSI definitions and who had a
first positive blood culture result 2 days after hospital discharge
NOTE. The definitions are derived from Friedman et al. [21], Shorr et al. [5], and Siegman-Igra
et al. [22]. CA-BSI, community-acquired BSI; HA-BSI; hospital-acquired BSI; HCA-BSI, health care–
associated BSI; IV, intravenous.
have investigated risk factors for S. aureus BSI–associated IE,
and these are summarized in table 2. Major risk factors include
persistent bacteremia, persistent fever, an unknown source of
infection, the presence of prosthetic heart valves, and com-
munity acquisition. A previous episode of IE and injection drug
use have also been defined as risk factors for IE [38, 40–42].
Although the risk of IE is higher among patients with prosthetic
heart valves (43%–51%) than among those without these de-
vices [39, 43], S. aureus is currently the primary etiological
agent for all types of IE [6], highlighting its ability to infect
native valves, even those that are structurally normal [44].
The absence of a documented source of infection and the
development of complications are independent risk factors for
mortality and are more frequently associated with CA-BSI than
with nosocomial BSI [24]. Recent data show that the overall
increase in the incidence of S. aureus BSI is mainly attributable
to an increase in the incidence of MRSA infection [24, 45] and
that patients with MRSA BSI have worse prognoses and in-
creased risk of mortality, compared with those with BSI caused
by methicillin-susceptible S. aureus (MSSA) or other pathogens
[5, 17, 41, 46]. The worse prognoses and increased mortality
may be attributable, in part, to a higher incidence of comor-
bidities among patients with MRSA infection and to the fact
that patients with MRSA infection more frequently receive in-
appropriate empirical therapy or are treated with vancomycin,
which has been associated with treatment failure and relapse
of infection [47–52]. Among patients with MRSA BSI treated
with vancomycin, those for whom the vancomycin MIC is1.5
mg/mL have the highest risk of treatment failure [50] and mor-
tality [51]. Overall, the prognosis of S. aureus IE is poorer when
there are associated complications that preclude valve replace-
ment surgery (e.g., persistent bacteremia, embolic events, and
multiorgan failure) or when the patient has non–IE-related
comorbidities [53]. Similarly, MRSA IE is associated with a
worse prognosis, compared with MSSA IE (table 3) [6, 53, 54].
The mortality associated with MRSA IE varies depending on
the patient population but is particularly high among patients
with nosocomial infections (67%) [53]. A study that reviewed
outcomes in patients with MRSA IE who were receiving he-
modialysis reported a mortality rate of 90%; however, this ret-
rospective analysis included only 10 patients who were receiving
hemodialysis [54].
Although the risk of developing complications of secondary
BSI is lower than the risk of developing complications of pri-
mary BSI, the complications of secondary BSI are not insig-
nificant. Catheter-related S. aureus BSI is associated with a 13%
incidence of hematogenous complications, including septic ar-
thritis, vertebral osteomyelitis, and IE [55]. An experimental
model of IE revealed that both the percentage of damaged heart
valves that subsequently became infected and the number of
colony-forming units per valve were related to the size of the
inocula [56]. Consistent with this finding, the risk of developing
IE increases as the duration of time that the source of infection
remains untreated increases, probably because of an increased
number of bacteria entering the bloodstream [57]. Prompt
management of the primary source of infection in secondary
BSIs (e.g., removal of an intravenous catheter) is therefore rec-
ommended to reduce the risk of complications. However, con-
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Figure 1. Primary bloodstream infections (BSIs) as a continuum in which secondary seeding can give rise to complications. (1) Episodes of spontaneous
low-grade bacteremia may occur repeatedly during normal activities, usually without clinical repercussions. The portal of entry is breached in colonized
skin or mucosa. (2) Occasionally, such spontaneous events may result in organ seeding, creating an infected microfocus that will enlarge over time.
(3) The microfocus is responsible for discharging bacteria at an increasing frequency, resulting first in primary BSI and then in bacteremia with an
identifiable focus.
tinued vigilance is still required, because undetected seeding of
bacteria to other sites may have already occurred, and com-
plications may not become apparent until days or weeks after
the initial seeding.
The clinical presentation of S. aureus BSI in children is dif-
ferent from that in adults [58, 59]. One study revealed that,
although children had similar rates of primary and secondary
BSIs [59], 86% of S. aureus BSIs in infants without a preexisting
medical condition had a clinically recognized focus, mostly in
osteoarticular sites (59%). In that study, very few children de-
veloped IE (1.4% of children), and the mortality associated
with S. aureus BSIs in infants was low (∼0.7%). However, higher
prevalence of IE and mortality rates have been reported for
pediatric patients with S. aureus bacteremia. In a prospective
single-center study, 11.8% of children with S. aureus bacteremia
had definite IE, and 7.8% had possible IE; the combined mor-
tality rate was 40% among children with definite or possible
IE [60].
ORIGIN OF S. AUREUS ISOLATES IN BSIS
The nares are the main reservoir for S. aureus in humans.
Approximately 25% of healthy adults are colonized with S.
aureus, and 1.5%–3.0% are persistently colonized with MRSA
[61–63]. Permanent colonization of the nares is more frequent
in infants than in adults [64], and persistent carriers are usually
members of groups at high risk of infection, such as patients
with type I diabetes mellitus, injection drug users, and patients
receiving hemodialysis who have extensive skin disease [65–
67].
Nasal carriage plays an important role in the pathogenesis
of infection. It is associated with an increased risk of S. aureus
infection after surgery and in patients receiving renal replace-
ment therapy comprising either ambulatory peritoneal dialysis
or hemodialysis. One study demonstrated that the vast majority
(82.2%) of isolates from cultures of blood samples from pa-
tients with S. aureus BSI were indistinguishable from the isolates
from nares samples from the same patients, and 85.7% of S.
aureus nasal carriers who developed BSI had identical strains
at both sites [64].
Farm animals may represent an additional reservoir for CA-
MRSA strains. Recent studies in Europe and worldwide have
demonstrated the transmission of MRSA from pigs and veal
calves to farmers and veterinarians [68, 69].
PREVENTION AND TREATMENT OF S. AUREUS
BSIS
Carriers of S. aureus who undergo medical procedures are at
risk of developing bacteremia. Coello et al. [70] found that
∼11% of patients who were colonized with MRSA at hospital
admission developed nosocomial MRSA infection, and Pujol
et al. [71] found that ∼22% of patients colonized with S. aureus
at the time of admission to the intensive care unit developed
bacteremia. MRSA infection was associated with previous use
of antibiotics, the presence of ulcers or surgical wounds, and
the use of tubes, drains, and catheters [70, 71]. Early com-
mentators suggested that the highest risk of bacteremia occurs
during the period immediately after colonization; however,
more-recent studies suggest that the risk of infection and mor-
tality may be higher during the first year after colonization
(33%) than it is during the second (27%) and third (16%)
years [72] or that the risk of infection and mortality may be
completely unrelated to the duration of MRSA colonization
[73].
These data support the use of methods for decolonization
S250 • CID 2009:48 (Suppl 4) • del Rio et al.
Table 2. Risk factors for infective endocarditis after Staphylococcus aureus
bacteremia
Reference Year
No. of
patients Risk factor
Fowler et al. [35] 2003 724 Community acquisition, persistent fever,
persistent bacteremia, and skin exami-
nation findings that suggest acute sys-
temic infection
Chang et al. [38] 2003 505 Valvular heart disease, prosthetic valve,
previous infective endocarditis, injection
drug use, unknown source of bacter-
emia, persistent bacteremia, nonwhite
race, and community acquisition
El-Ahdab et al. [39] 2005 51a Persistent fever and persistent bacteremia
Hill et al. [40] 2007 132 Unknown source of bacteremia, pros-
thetic valve, persistent fever, and per-
sistent bacteremia
a All of these patients had prosthetic valves.
in MRSA nasal carriers who are admitted to the hospital or
who are scheduled to undergo inpatient procedures in the near
future [73]. Nasal decolonization is effective in a high pro-
portion of patients. A success rate of 87% was achieved after
implementation of a decolonization regimen that combined
topical treatments (e.g., mupirocin nasal ointment, chlorhex-
idine mouth rinse, and full-body washes with chlorhexidine
soap for 5 days) for nasal and skin colonization with oral van-
comycin and trimethoprim-sulphamethoxazole for intestinal
and urinary colonization, respectively, and povidone-iodine,
chlorhexidine ovula, or octenidine solution for vaginal colo-
nization [74, 75]. With regard to topical mupirocin, a recent
study reported a high incidence of resistance in MRSA strains
(resistance in 13% of strains and high-level resistance in 9%),
despite low levels of in-hospital mupirocin use [76]. Oral ad-
ministration of rifampicin and doxycycline has also proven to
be successful for decolonization [77]. Guidelines recommend
screening for MRSA, with prophylaxis for patients at high risk
of infection, and preventative measures, such as improved nurs-
ing practices, the use of aseptic techniques for catheter place-
ment, and decontamination practices, have proved to be ef-
fective against both MRSA and MSSA colonization [78–80].
However, the long-term effects of MRSA decolonization on the
incidence of infection remain unclear.
Immunotherapy is a potential preventative strategy that has
attracted commercial interest. Several candidates are being in-
vestigated in clinical trials; however, 2 of the most advanced
compounds—the StaphVAX vaccine and INH-A21, a polyclo-
nal antibody—did not demonstrate adequate protection in
phase III clinical trials [81–83]. Trials of the StaphVAX vaccine
in patient populations at high risk of infection have recently
been completed, and publication of the results is anticipated
[84]. In addition to the difficulties in implementing vaccination
and/or prophylaxis against an evolving and virulent pathogen
such as S. aureus, many relevant epidemiological questions re-
main unanswered. Which populations should be targeted for
vaccination? What is the risk of S. aureus BSI in healthy carriers?
What is the potential value of MRSA screening for all patients
admitted to the hospital or for hospital inpatients in settings
with a high prevalence of CA-MRSA or nosocomial MRSA
infection, respectively, and what sites should be tested? Which
prophylactic treatments are best able to penetrate into the mu-
cosal cells of the nostrils, and are the vaccines able to elicit
immunity at this site?
The optimal strategies for treatment of S. aureus bacteremia
and BSI are still a matter of much debate, and this subject is
covered in more detail in an article by Corey [85] in this sup-
plement. No clear guidelines exist for the treatment of S. aureus
BSI without associated secondary infections; however, treat-
ment for at least 2 weeks with penicillinase-stable b-lactam
antibiotics (e.g., nafcillin or cloxacillin) has been recommended
for MSSA infection [86]. When there are secondary foci, treat-
ment should adhere to the recommendations for the specific
complications [87–90]. The proportion of MRSA isolates is
increasing in many countries [91]. Vancomycin is currently the
recommended treatment for MRSA BSI, but the rate of treat-
ment failure remains high [8]. Vancomycin is less effective than
b-lactams against MSSA infection [49, 92], and there is evidence
of a vancomycin MIC creep for both MSSA and MRSA [93].
This evidence has caused increasing concerns about the ap-
propriateness of vancomycin for the treatment of both MSSA
and MRSA infections [51, 52, 94] and has led to consideration
of the use of more-recently introduced antibiotic agents, such
as daptomycin, which has demonstrated efficacy comparable
to that of the standard of care for MSSA or MRSA complicated
skin and soft-tissue infections and bacteremia with or without
IE [8, 95]. The limited success of current treatments for MRSA
infection indicates that many challenges are yet to be overcome.
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Table 3. Frequency of surgical procedures and mortality associated with methicillin-
susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA)
infective endocarditis (IE).
Study, type of IE Type of valve(s)
No. of
patients
Frequency of
surgical procedures, %
In-hospital
mortality, %
Fowler et al. [6]
MSSA NV and PV 283 37.5 23.3
MRSA NV and PV 141 39.0 29.8
Miro´ et al. [37]
MSSA NV 248 24.6 23.2
MRSA NV 43 25.6 37.2
Hill et al. [53]
MSSA NV and PV 56 68 30a
MRSA NV and PV 16 38 56a
NOTE. NV, native valve; PV, prosthetic valve.
a Six-month mortality.
CONCLUSIONS
To fully appreciate the risks associated with S. aureus BSIs and
the implications of these risks for management strategies, the
progression from bacteremia to BSI should be considered as a
continuum of pathology. The risk of developing MSSA or
MRSA bacteremia is related to the source of infection; MRSA
bacteremia is more frequently associated with health care en-
vironments, whereas MSSA bacteremia is more frequently as-
sociated with community settings. Primary S. aureus BSIs are
often the expression of deep-seated infections that have not
been diagnosed and, thus, deserve serious consideration. S.
aureus carriers are at high risk of developing BSIs, and patients
with underlying conditions have an increased risk of developing
associated complications. Improved eradication and control
strategies are needed to successfully combat the challenges pre-
sented by S. aureus BSIs.
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